166 related articles for article (PubMed ID: 33084997)
1. Clinical Characteristics and Management of 50 Patients with Anti-GAD Ataxia: Gluten-Free Diet Has a Major Impact.
Hadjivassiliou M; Sarrigiannis PG; Shanmugarajah PD; Sanders DS; Grünewald RA; Zis P; Hoggard N
Cerebellum; 2021 Apr; 20(2):179-185. PubMed ID: 33084997
[TBL] [Abstract][Full Text] [Related]
2. GAD antibody-associated neurological illness and its relationship to gluten sensitivity.
Hadjivassiliou M; Aeschlimann D; Grünewald RA; Sanders DS; Sharrack B; Woodroofe N
Acta Neurol Scand; 2011 Mar; 123(3):175-80. PubMed ID: 20456245
[TBL] [Abstract][Full Text] [Related]
3. Stiff Person Syndrome and Gluten Sensitivity.
Hadjivassiliou M; Zis P; Sanders DS; Hoggard N; Sarrigiannis PG
Nutrients; 2021 Apr; 13(4):. PubMed ID: 33923904
[TBL] [Abstract][Full Text] [Related]
4. Auto-immune cerebellar ataxia with anti-GAD antibodies accompanied by de novo late-onset type 1 diabetes mellitus.
Bayreuther C; Hieronimus S; Ferrari P; Thomas P; Lebrun C
Diabetes Metab; 2008 Sep; 34(4 Pt 1):386-8. PubMed ID: 18583169
[TBL] [Abstract][Full Text] [Related]
5. Vertical nystagmus associated with glutamic acid decarboxylase antibodies responding to cyclophosphamide.
Baizabal-Carvallo JF; Alonso-Juarez M
J Neuroimmunol; 2018 Apr; 317():5-7. PubMed ID: 29501085
[TBL] [Abstract][Full Text] [Related]
6. Autoantibodies to glutamic acid decarboxylase in three patients with cerebellar ataxia, late-onset insulin-dependent diabetes mellitus, and polyendocrine autoimmunity.
Saiz A; Arpa J; Sagasta A; Casamitjana R; Zarranz JJ; Tolosa E; Graus F
Neurology; 1997 Oct; 49(4):1026-30. PubMed ID: 9339684
[TBL] [Abstract][Full Text] [Related]
7. Effect of gluten-free diet on cerebellar MR spectroscopy in gluten ataxia.
Hadjivassiliou M; Grünewald RA; Sanders DS; Shanmugarajah P; Hoggard N
Neurology; 2017 Aug; 89(7):705-709. PubMed ID: 28724585
[TBL] [Abstract][Full Text] [Related]
8. Spectrum of neurological syndromes associated with glutamic acid decarboxylase antibodies: diagnostic clues for this association.
Saiz A; Blanco Y; Sabater L; González F; Bataller L; Casamitjana R; Ramió-Torrentà L; Graus F
Brain; 2008 Oct; 131(Pt 10):2553-63. PubMed ID: 18687732
[TBL] [Abstract][Full Text] [Related]
9. Spontaneous downbeat nystagmus as a clue for the diagnosis of ataxia associated with anti-GAD antibodies.
Vale TC; Pedroso JL; Alquéres RA; Dutra LA; Barsottini OG
J Neurol Sci; 2015 Dec; 359(1-2):21-3. PubMed ID: 26671081
[TBL] [Abstract][Full Text] [Related]
10. [A new case of cerebellar ataxia with anti-GAD antibodies treated with corticosteroids and initially seronegative].
Birand B; Cabre P; Bonnan M; Olindo S; Smadja D
Rev Med Interne; 2006 Aug; 27(8):616-9. PubMed ID: 16797794
[TBL] [Abstract][Full Text] [Related]
11. Cerebellar ataxia and epilepsy with anti-GAD antibodies: treatment with IVIG and plasmapheresis.
Georgieva Z; Parton M
BMJ Case Rep; 2014 Jan; 2014():. PubMed ID: 24419643
[TBL] [Abstract][Full Text] [Related]
12. The Significance of Low Titre Antigliadin Antibodies in the Diagnosis of Gluten Ataxia.
Hadjivassiliou M; Grünewald RA; Sanders DS; Zis P; Croal I; Shanmugarajah PD; Sarrigiannis PG; Trott N; Wild G; Hoggard N
Nutrients; 2018 Oct; 10(10):. PubMed ID: 30301184
[TBL] [Abstract][Full Text] [Related]
13. Intravenous immunoglobulin and rituximab for cerebellar ataxia with glutamic acid decarboxylase autoantibodies.
Planche V; Marques A; Ulla M; Ruivard M; Durif F
Cerebellum; 2014 Jun; 13(3):318-22. PubMed ID: 24218114
[TBL] [Abstract][Full Text] [Related]
14. Clinical characteristics of patients with cerebellar ataxia associated with anti-GAD antibodies.
Aguiar TS; Fragoso A; Albuquerque CR; Teixeira PF; Souza MV; Zajdenverg L; Alves-Leon SV; Rodacki M; Lima MA
Arq Neuropsiquiatr; 2017 Mar; 75(3):142-146. PubMed ID: 28355320
[TBL] [Abstract][Full Text] [Related]
15. Anti-glutamic acid decarboxylase (GAD) positive cerebellar Ataxia with transitioning to progressive encephalomyelitis with rigidity and myoclonus (PERM), responsive to immunotherapy: A case report and review of literature.
Jazebi N; Rodrigo S; Gogia B; Shawagfeh A
J Neuroimmunol; 2019 Jul; 332():135-137. PubMed ID: 31015081
[TBL] [Abstract][Full Text] [Related]
16. Transient Neurological Symptoms Preceding Cerebellar Ataxia with Glutamic Acid Decarboxylase Antibodies.
Muñiz-Castrillo S; Vogrig A; Joubert B; Pinto AL; Gonçalves D; Chaumont H; Rogemond V; Picard G; Fabien N; Honnorat J
Cerebellum; 2020 Oct; 19(5):715-721. PubMed ID: 32592031
[TBL] [Abstract][Full Text] [Related]
17. Neurologic disorders associated with anti-glutamic acid decarboxylase antibodies: A comparison of anti-GAD antibody titers and time-dependent changes between neurologic disease and type I diabetes mellitus.
Nakajima H; Nakamura Y; Inaba Y; Tsutsumi C; Unoda K; Hosokawa T; Kimura F; Hanafusa T; Date M; Kitaoka H
J Neuroimmunol; 2018 Apr; 317():84-89. PubMed ID: 29338930
[TBL] [Abstract][Full Text] [Related]
18. Gluten ataxia in perspective: epidemiology, genetic susceptibility and clinical characteristics.
Hadjivassiliou M; Grünewald R; Sharrack B; Sanders D; Lobo A; Williamson C; Woodroofe N; Wood N; Davies-Jones A
Brain; 2003 Mar; 126(Pt 3):685-91. PubMed ID: 12566288
[TBL] [Abstract][Full Text] [Related]
19. Low-Titre GAD Antibody-Associated Late-Onset Cerebellar Ataxia with a Significant Clinical Response to Intravenous Immunoglobulin Treatment.
Petrijan T; Menih M
Cerebellum; 2017 Aug; 16(4):868-871. PubMed ID: 28321713
[TBL] [Abstract][Full Text] [Related]
20. Presynaptic inhibition of cerebellar GABAergic transmission by glutamate decarboxylase autoantibodies in progressive cerebellar ataxia.
Takenoshita H; Shizuka-Ikeda M; Mitoma H; Song S; Harigaya Y; Igeta Y; Yaguchi M; Ishida K; Shoji M; Tanaka M; Mizusawa H; Okamoto K
J Neurol Neurosurg Psychiatry; 2001 Mar; 70(3):386-9. PubMed ID: 11181864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
